<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25714" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nephrotoxic Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Janak B.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sapra</surname>
            <given-names>Amit</given-names>
          </name>
          <aff>Southern Illinois University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Janak Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amit Sapra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25714.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Numerous drugs used to manage and treat multiple diseases, including hypertension, diabetes, and other pathologies, are nephrotoxic. These agents are in various classes and categories of medication. This activity reviews the indications, action, and contraindications for nephrotoxic drugs as a valuable agent in choosing key treatment strategies. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., dosing, monitoring, relevant interactions) pertinent for healthcare team members in the care of patients with renal pathologies and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the most common drug classes that can contribute to an increased incidence of renal damage.</p></list-item><list-item><p>Identify the main drugs that are more likely to be nephrotoxic and how clinicians should proceed with treatment.</p></list-item><list-item><p>Outline some renal pathologies that can become a result of nephrotoxic drug administration.</p></list-item><list-item><p>Review the importance of care coordination amongst the interprofessional team to improve outcomes for patients with renal disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25714&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25714">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25714.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Reports of acute and chronic kidney diseases are increasing in the U.S. and various parts of the world. When looking for a critical metric to understand when not to treat&#x000a0;using a nephrotoxic medication, the standard&#x000a0;is set at an eGFR less than 60 mL/min per 1.73 m^2.</p>
        <p>Nephrotoxic medications can elicit damage to the kidney via various mechanisms, including alteration in its structure and function. When evaluating the primary etiologies in renal injury, the incidence of drug-induced toxicity has accounted for 20% of all-cause incidents. Besides, when nephrotoxicity from pharmacologic agents is further examined, evidence has shown it to be one of the chief etiologies in intrinsic renal failure aside from the second most common cause, infection.<xref ref-type="bibr" rid="article-25714.r1">[1]</xref>&#x000a0;Numerous drugs go under the category of nephrotoxic medications. Tables 1 through 3 list the most common drugs that can damage the kidneys and their drug class.</p>
        <p>The more significant percentage of individuals affected by these agents come from the over 70-year-old category. With the aging life expectancy in the United States, we need to choose pharmacologically appropriate agents for our aging population with declining renal functions.</p>
      </sec>
      <sec id="article-25714.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Drugs such as those listed previously elicit damage to renal tissue via numerous mechanisms. A few of these mechanisms include impairment of perfusion, inflammation induction, free radicals formation, and many other mechanisms.<xref ref-type="bibr" rid="article-25714.r2">[2]</xref><xref ref-type="bibr" rid="article-25714.r3">[3]</xref>&#x000a0;A few of the most common mechanisms of action appear below:</p>
        <p>
<bold>GFR Alteration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A few examples include the effect of ACE inhibitors, ARBs, cyclosporins, NSAIDs, and tacrolimus that affect the intraglomerular hemodynamics via the alteration of the glomerular filtration rate.<xref ref-type="bibr" rid="article-25714.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Tubular Cell Toxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The presence of certain pharmaceutical agents may damage the cells of the proximal tubules via free radical formation, mitochondrial damage, and transport systems damage. These agents include aminoglycosides, amphotericin B, adefovir, cisplatin, and foscarnet.<xref ref-type="bibr" rid="article-25714.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Interstitial Nephritis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>NSAIDs and rifampin are common causes of acute interstitial tissue inflammation. Chronic forms result from agents, including analgesics, anticancer drugs, lithium, and calcineurin inhibitors.<xref ref-type="bibr" rid="article-25714.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Crystal Nephropathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Antivirals such as acyclovir and antibiotics such as ampicillin have been common etiologies of insoluble crystal formation within renal tissue.<xref ref-type="bibr" rid="article-25714.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>A more detailed list is present in tables 1-3.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25714.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The majority of the drugs described are oral formulations, with a few minor ones available in other dosage forms.</p>
      </sec>
      <sec id="article-25714.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>As adverse reactions are the main subject, the full list of renal damage locations appears in tables 1 and 2. The primary sites include the glomerulus and proximal and distal convoluted renal tubules.</p>
      </sec>
      <sec id="article-25714.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to drug administration include the presence of chronic renal disease or end-stage renal disease.<xref ref-type="bibr" rid="article-25714.r8">[8]</xref>&#x000a0;As previously mentioned, the presence of a GFR below 60 ml/min per 1.73 m^2 for the definition of moderate chronic renal disease and a creatinine clearance below 30 mL/min as seen in severe chronic kidney disease are critical metrics for treatment judgment.&#x000a0;</p>
      </sec>
      <sec id="article-25714.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>General guidelines recommend determining baseline renal function before and after initiation of nephrotoxic pharmaceutical agents. The most common formula used in the calculation of glomerular filtration rate is the Schwartz formula. Calculation of GFR (mL/min/1.73 m^2= length (cm) X potassium /serum creatinine (mg/dL). To use clinician judgment in determining whether to withdraw a nephrotoxic agent, we aim to keep the GFR above the chronic kidney disease threshold of 60.<xref ref-type="bibr" rid="article-25714.r2">[2]</xref></p>
        <p>Also, many biomarkers have become available to assess renal toxicity further. A few of these are as follows:</p>
        <p>
<bold>Urine Proteins and Enzymatic activity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alanine aminopeptidase, alpha-glutathione-S-transferase, &#x003b3;-glutamyl transpeptidase, alkaline phosphatase, N-acetyl-D-glucosaminidase, and &#x003c0;-glutathione-S-transferase 18294749.</p>
          </list-item>
        </list>
        <p>
<bold>Proteinuria</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>An increase in the amount of high or low molecular proteins in urine testing is another key diagnostic tool. Typically high and low molecular weight proteins get reabsorbed before being released into the proximal convoluted tubule of the nephron. High molecular weight proteins that signal renal damage include albumin, transferrin, and immunoglobulin G. Low molecular proteins diagnostic for renal damage include a1-microglobulin, B2-microglobulin, cystatin-C, and retinol-binding protein.<xref ref-type="bibr" rid="article-25714.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Kidney injury Molecule 1</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>KIM1 is a type 1 glycoprotein rapidly detected in urine upon damage to tissue that allows for the measurement of proximal renal tubule damage. Greater sensitivity than traditional methods of measuring renal damage such as BUN, Creatinine, and the presence of proteinuria.<xref ref-type="bibr" rid="article-25714.r5">[5]</xref><xref ref-type="bibr" rid="article-25714.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Neutrophil Gelatinase-associated Lipocalin</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>NGAL is synthesized during granulocyte maturation and as a byproduct of tissue inflammation and damage, especially in the proximal renal tubule. Acute kidney injury can be measured and diagnosed earlier with this biomarker. Caution is necessary as NGAL also elevates general inflammatory and infectious processes.</p>
          </list-item>
        </list>
        <p>
<bold>Type 4 Collagen</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 4 collagen is present in the basement membrane of the glomerulus. The presence of type 4 collagen in the urine may serve as a critical marker in glomerular membrane damage.<xref ref-type="bibr" rid="article-25714.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Osteopontin</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Osteopontin is a bone phosphoprotein present in the bone that is useful&#x000a0;in measuring damage from certain nephrotoxic drugs. A few of these drugs include cisplatin, angiotensin-2 receptor blockers, cyclosporin, gentamicin, and puromycin.<xref ref-type="bibr" rid="article-25714.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Clusterin</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clusterin is a glycoprotein used to measure proximal and distal convoluted tubule damage via presence in the urine.</p>
          </list-item>
        </list>
        <p>Preventative measures aimed at decreasing the incidence of significant nephrotoxic effects include oral administration, low effective doses, and short therapy. Furthermore, the dose can be reduced or discontinued in the setting of toxicity.<xref ref-type="bibr" rid="article-25714.r13">[13]</xref></p>
      </sec>
      <sec id="article-25714.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In the event that there is a significant nephrotoxic event that is changing the GFR, isotonic repletion can be provided to help dilute serum drug concentrations during therapy.<xref ref-type="bibr" rid="article-25714.r2">[2]</xref>&#x000a0;Infants and young children are also a chief demographic in drug-induced nephrotoxicity. Toxicity can present with many different types of renal pathology:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute and chronic interstitial nephritis</p>
          </list-item>
          <list-item>
            <p>Proximal renal tubular acidosis</p>
          </list-item>
          <list-item>
            <p>Acute and chronic tubular necrosis</p>
          </list-item>
          <list-item>
            <p>Glomerulonephritis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Crystal nephropathy</p>
          </list-item>
          <list-item>
            <p>Nephrotic syndrome</p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis&#x000a0;</p>
          </list-item>
        </list>
        <p>Understanding the different regions of renal damage may allow for a more targeted approach to renal injury, including the development of pharmaceutical agents with greater benefit and decreased toxicity.<xref ref-type="bibr" rid="article-25714.r14">[14]</xref><xref ref-type="bibr" rid="article-25714.r15">[15]</xref></p>
      </sec>
      <sec id="article-25714.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Understanding nephrotoxic pharmaceutical agents is a key component of the interprofessional healthcare team and a patient-centered approach. Starting&#x000a0;with the clinicians who prescribe the drugs to the pharmacists who dispense the drug and the nurses who administer the drugs, there is a chain of transport where many healthcare providers are a part of patient care. Knowing the toxic effects, these agents may&#x000a0;significantly impact the quality of care a patient receives. The nurse should be aware of which drugs are nephrotoxic, especially with patients that already have renal impairment. They can counsel the patients regarding these agents and report any issues back to the prescriber. The pharmacist can reinforce this counsel while also performing total medication reconciliation, checking doses (especially those that require renal adjustment), and contacting the clinician if there are any issues. These types of interprofessional collaborations will prevent renal toxicity from occurring when it need not. [Level 5]</p>
        <p>Furthermore, through the understanding of preventative measures and thresholds for toxicity, healthcare providers may enhance patient safety. Lastly, with the development of numerous biomarkers targeting types of renal damage, response to treatment can be monitored when knowledge of the potential renal effects of medication is known. [Level 1]&#x000a0;<xref ref-type="bibr" rid="article-25714.r14">[14]</xref><xref ref-type="bibr" rid="article-25714.r16">[16]</xref></p>
      </sec>
      <sec id="article-25714.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25714&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25714">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25714/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25714">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25714.s11">
        <fig id="article-25714.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Nephrotoxic Medication Table 01 Contributed by Janak Patel, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Nephrotoxic__Medication__Table__01" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25714.s12">
        <fig id="article-25714.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Nephrotoxic Medication Table 02 Contributed by Janak Patel, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__2__Nephrotoxic" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25714.s13">
        <fig id="article-25714.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Nephrotoxic Medication Table 03 Contributed by Janak Patel, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__3__Nephrotoxic" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25714.s14">
        <title>References</title>
        <ref id="article-25714.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaufman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dhakal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hamburger</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Community-acquired acute renal failure.</article-title>
            <source>Am J Kidney Dis</source>
            <year>1991</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-8</page-range>
            <pub-id pub-id-type="pmid">1992662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghane Shahrbaf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Assadi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced renal disorders.</article-title>
            <source>J Renal Inj Prev</source>
            <year>2015</year>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">26468475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schetz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dasta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Golper</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced acute kidney injury.</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>555</fpage>
            <page-range>555-65</page-range>
            <pub-id pub-id-type="pmid">16292059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced nephropathy: an update.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>689</fpage>
            <page-range>689-706</page-range>
            <pub-id pub-id-type="pmid">16011448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Stack</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Kunis</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palecki</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hoh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Toxic acute tubular necrosis following treatment with zoledronate (Zometa).</article-title>
            <source>Kidney Int</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>281</fpage>
            <page-range>281-9</page-range>
            <pub-id pub-id-type="pmid">12787420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perneger</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Klag</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs.</article-title>
            <source>N Engl J Med</source>
            <year>1994</year>
            <month>Dec</month>
            <day>22</day>
            <volume>331</volume>
            <issue>25</issue>
            <fpage>1675</fpage>
            <page-range>1675-9</page-range>
            <pub-id pub-id-type="pmid">7969358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced renal failure: a focus on tubulointerstitial disease.</article-title>
            <source>Clin Chim Acta</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>351</volume>
            <issue>1-2</issue>
            <fpage>31</fpage>
            <page-range>31-47</page-range>
            <pub-id pub-id-type="pmid">15563870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ingrasciotta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sultana</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giorgianni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caputi</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Arcoraci</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tari</surname>
                <given-names>DU</given-names>
              </name>
              <name>
                <surname>Linguiti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perrotta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nucita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pellegrini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cavagna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Trifir&#x000f2;</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>e89072</fpage>
            <pub-id pub-id-type="pmid">24558471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferguson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Bonventre</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers of nephrotoxic acute kidney injury.</article-title>
            <source>Toxicology</source>
            <year>2008</year>
            <month>Mar</month>
            <day>20</day>
            <volume>245</volume>
            <issue>3</issue>
            <fpage>182</fpage>
            <page-range>182-93</page-range>
            <pub-id pub-id-type="pmid">18294749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaidya</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bonventre</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers of acute kidney injury.</article-title>
            <source>Annu Rev Pharmacol Toxicol</source>
            <year>2008</year>
            <volume>48</volume>
            <fpage>463</fpage>
            <page-range>463-93</page-range>
            <pub-id pub-id-type="pmid">17937594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nerlich</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Schleicher</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Wiest</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Timpl</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Immunohistochemical localization of collagen VI in diabetic glomeruli.</article-title>
            <source>Kidney Int</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>1648</fpage>
            <page-range>1648-56</page-range>
            <pub-id pub-id-type="pmid">7933812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alchi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nishi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sakatsume</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gejyo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Osteopontin expression in acute renal allograft rejection.</article-title>
            <source>Kidney Int</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>886</fpage>
            <page-range>886-96</page-range>
            <pub-id pub-id-type="pmid">15698428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Nzerue</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>How to prevent, recognize, and treat drug-induced nephrotoxicity.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>289</fpage>
            <page-range>289-90, 293-4, 296-7 passim</page-range>
            <pub-id pub-id-type="pmid">11996200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced nephrotoxicity and its biomarkers.</article-title>
            <source>Biomol Ther (Seoul)</source>
            <year>2012</year>
            <month>May</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-72</page-range>
            <pub-id pub-id-type="pmid">24130922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choudhury</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Drug-associated renal dysfunction and injury.</article-title>
            <source>Nat Clin Pract Nephrol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>80</fpage>
            <page-range>80-91</page-range>
            <pub-id pub-id-type="pmid">16932399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25714.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonventre</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Schmouder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dieterle</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Next-generation biomarkers for detecting kidney toxicity.</article-title>
            <source>Nat Biotechnol</source>
            <year>2010</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>436</fpage>
            <page-range>436-40</page-range>
            <pub-id pub-id-type="pmid">20458311</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
